Can Substance Use Disorder Go Into Remission? Diagnosis and Prognosis

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

Yes. Substance use disorder (SUD) can enter remission, and sustained improvement is possible across different substance classes and levels of initial severity. In DSM-5-TR terminology, early remission means that a person who previously met diagnostic criteria has experienced at least three months but less than twelve months without meeting any of the disorder's diagnostic criteria except craving. Sustained remission means that this pattern has lasted twelve months or longer. A person may still experience craving, receive ongoing medication, or need support while being in remission. The course is assessed clinically and remains open to change. DSM-5 diagnostic rationale; SAMHSA clinical guidance.

The answer carries two equally important implications. Remission is a legitimate clinical state rather than an informal declaration that a problem is over. Its meaning depends on the diagnostic system, the substance involved, the observed period, and the quality of assessment. Prognosis concerns the probability and pattern of continued improvement, recurrence, and functioning over time. It is informed by research across populations but determined for an individual through clinical history, health, circumstances, and treatment response.

What remission means in substance use disorder

Substance use disorder is a substance-specific clinical diagnosis involving a problematic pattern of use and clinically significant impairment or distress. DSM-5-TR assesses symptoms such as loss of control, unsuccessful attempts to reduce use, craving, neglected obligations, continued use despite harmful consequences, hazardous use, and diminished participation in other activities. The complete diagnostic assessment concerns the substance and the relevant twelve-month period. The common DSM-5-TR severity framework counts two or three criteria as mild, four or five as moderate, and six or more as severe; clinician judgment remains necessary to establish applicability and exclude medically expected tolerance or withdrawal arising solely from appropriately supervised prescribed medication. NIAAA clinical overview; DSM-5 diagnostic rationale.

Remission describes the current course of a disorder that was previously present. It is not established merely by reporting a period without taking a substance, by passing a screening questionnaire, or by having a negative toxicology test. Conversely, a person with a firmly documented past disorder may meet remission criteria while remaining in pharmacological treatment or experiencing occasional craving. The question is whether the full history supports a previous diagnosis and whether relevant criteria, other than craving, have remained absent throughout the specified interval.

Substance use, risky use, physical dependence, and addiction

Substance use is the act or pattern of consuming a psychoactive substance. Risky or hazardous use describes exposure that increases the likelihood of harm; substance misuse is a variable clinical and everyday label, often referring to use outside instructions or in harmful circumstances. Neither term establishes the diagnostic threshold of SUD. Addiction is commonly used for the more compulsive or severe clinical pattern, but its boundaries vary across professional and research settings. Physical dependence is physiological adaptation, often revealed by withdrawal when a substance is stopped; tolerance is a diminished response or need for more exposure to achieve the same effect. Dependence and tolerance may occur during legitimate medical care without compulsive use. ASAM benzodiazepine guideline; NIH language guide.

Withdrawal is the physiological and psychological syndrome that can follow a reduction or cessation of exposure. Intoxication is an acute effect of a substance, and overdose is a potentially toxic exposure that can become life-threatening. These events require assessment on their own terms. A resolved withdrawal episode is not equivalent to remission, and detoxification by itself does not establish recovery. The distinction matters especially for alcohol, benzodiazepines, opioids, and combinations of sedating drugs.

DSM-5-TR diagnostic criteria for early and sustained remission

The DSM framework recognizes early remission after at least three consecutive months but before twelve months have passed without meeting any SUD diagnostic criterion other than craving. Sustained remission begins after twelve or more consecutive months under the same condition. Craving is allowed because conditioned urges can persist after behavior and other clinical symptoms have improved. The duration applies to the interval during which the remission conditions are met, not simply the number of months since a patient first entered treatment. Hasin et al. diagnostic recommendations; SAMHSA, Counseling Approaches to Promote Recovery.

A useful timeline illustrates the formal distinction. A person diagnosed with alcohol use disorder who has experienced seven continuous months without DSM diagnostic symptoms apart from craving can qualify for early remission, provided the previous diagnosis was established and the clinical assessment supports the reported course. If the same conditions continue for thirteen months, sustained remission may apply. After six symptom-free weeks, improvement can be substantial, but the DSM early-remission time threshold has not yet been reached. The label is not a reward for achieving a specific number of days; it is a standardized description of current diagnostic status.

Can craving persist during remission?

Yes. Craving is the explicit exception to the DSM remission rule. A cue-triggered urge can occur after months or years without the other symptoms required for active SUD. Its clinical significance depends on intensity, frequency, emotional impact, how the person responds, and whether it begins to affect behavior or functioning. Persistent craving warrants thoughtful care and monitoring, while craving alone does not cancel the DSM remission specifier. It also does not reliably predict an individual return to problematic use without additional information. DSM-5 diagnostic rationale.

Does remission require complete abstinence?

Not in the formal DSM-5-TR SUD remission definition. A person may cease meeting disorder criteria while still reporting some use, although the safety and clinical appropriateness of continued use depend heavily on the substance, prior severity, medical risks, and personal goals. Some research categorizes abstinent and nonabstinent remission separately. For opioids obtained outside medical treatment, even a single episode after abstinence may present fatal overdose risk, particularly following reduced tolerance. For alcohol, abstinence remains the safest goal in several medical circumstances, while reduction of heavy drinking is recognized as a meaningful outcome for other patients. Diagnostic remission should never be interpreted as an assurance that any level of exposure is safe. NIAAA recovery definition; CDC opioid treatment guidance.

Remission while receiving medication or living in a controlled environment

DSM-5-TR permits additional specifiers describing maintenance treatment or a controlled environment when applicable. Examples of maintenance treatment include medications used for opioid use disorder. Properly administered buprenorphine or methadone is evidence-based care, and receiving that care does not make a person clinically unable to achieve remission. The setting also matters: symptom absence while access to substances is highly restricted can describe genuine improvement, but its implications for life after leaving the setting require separate assessment. Clinical documentation should preserve these circumstances rather than assuming all periods with the same duration imply the same prognosis. DSM-5 rationale; CDC opioid treatment guidance.

DSM-5-TR and ICD-11: Why remission terminology differs

The World Health Organization's ICD-11 uses a different classification architecture for disorders due to substance use, including substance dependence and harmful patterns of use. Its dependence course specifiers cannot be treated as interchangeable with DSM-5-TR SUD remission. In the ICD-11 clinical descriptions, the course specifications for dependence on substances other than alcohol include current use, early full remission, sustained partial remission, and sustained full remission. Early full remission describes abstinence for between one and twelve months after prior dependence; sustained full remission requires at least twelve months of abstinence. Sustained partial remission concerns marked reduction in consumption over more than twelve months without meeting dependence requirements. Alcohol dependence has substance-specific course codes and should be checked separately when coding. WHO ICD-11 clinical requirements.

This difference is consequential. A clinician using DSM-5-TR might appropriately document sustained SUD remission based on the absence of all qualifying symptoms apart from craving, despite limited ongoing use. A clinician documenting ICD-11 dependence must follow that classification's specific abstinence and reduced-use requirements. Cross-study comparisons that pool both labels without harmonizing definitions may overstate agreement about who is in remission. Researchers must report the original diagnostic system, observation window, substance, and outcome criteria.

Remission, recovery, recurrence, relapse, and cure

Remission is a diagnostic-course designation. Recovery is a larger clinical and personal process involving reduced substance-related harm, health, social connection, autonomy, and everyday functioning. Recurrence refers to the reappearance of clinically significant problems after improvement; return to use describes renewed consumption and should be evaluated according to its substance-specific risks. Relapse is a widespread historical term, but current person-centered practice often prefers return to use or recurrence because the exact event can be specified without implying a uniform loss of progress. A single episode of renewed substance use and renewed fulfillment of diagnostic SUD criteria are different outcomes. SAMHSA recovery guidance; NIH language guidance.

Cure suggests a permanent end to vulnerability and a conclusion that future clinical reassessment is unnecessary. The DSM remission specifier makes a more precise statement about current criteria over an observed period. Some people maintain durable improvement for decades. Others experience intermittent symptoms, changes in substance use, or later episodes of care. Research supports the possibility of lasting resolution while acknowledging trajectories that differ across individuals. The concept of sustained remission allows improvement to be recorded without claiming that future risk has become zero.

Recovery involves more than a diagnosis

SAMHSA describes recovery across health, home, purpose, and community. In practice, those domains include medical stability, housing, meaningful activities, and supportive social relationships. A person may meet the formal diagnostic threshold for remission while struggling with depression, chronic pain, unstable housing, debt, or damaged relationships. Another may make substantial gains in functioning and harm reduction before achieving a DSM course specifier. Recording both diagnostic outcomes and lived functioning gives a fuller picture. SAMHSA About Recovery.

Alcohol research offers an additional distinction. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) defines recovery from alcohol use disorder, for research purposes, as pursuing both remission from DSM-5 AUD and cessation from heavy drinking. That framework recognizes recovery without obligatory abstinence in all cases, and it includes longer-term well-being. NIAAA also uses descriptive research phases, including initial, early, sustained, and stable recovery, that should not be mistaken for the two DSM-5-TR diagnostic remission specifiers. NIAAA research definitions; Hagman et al., 2022.

How clinicians establish and document remission

A diagnosis in remission is established through a detailed clinical history and review of the current course. The clinician first confirms that the individual previously met criteria for the relevant substance-specific disorder, ideally with dates, source documentation, and contextual information. The next step is to map the current and intervening symptoms against the applicable diagnostic criteria, identify the last period in which criteria were met, and determine whether the required remission interval has been continuous. The assessment should also describe current use or abstinence, prescribed medication, intoxication, withdrawal, co-occurring mental or medical conditions, safety, and functional outcomes.

Screening and structured assessment serve different purposes

Screening instruments such as AUDIT-C and ASSIST help identify possible alcohol- or substance-related risk and the need for further assessment. A clinical interview, appropriately structured diagnostic instruments, corroborating records when available and consented to, and individualized medical assessment establish a diagnosis and its course. Screening scores do not independently determine remission, and a normal laboratory result cannot prove the absence of all diagnostic criteria over a year. Likewise, biomarker abnormalities may reflect physiology, timing, other exposures, or medical conditions and need interpretation in context. NIAAA clinical overview; McCabe et al., 2018.

The role of time, history, and corroboration

Recall is imperfect, especially when symptoms occurred intermittently or during stressful periods. Clinicians may clarify the difference between craving and uncontrolled consumption, between an isolated return to use and meeting a wider syndrome, and between substance-induced symptoms and independent psychiatric conditions. Interviews should remain nonjudgmental so patients can report a difficult event without fearing that care will automatically end. When possible and appropriate, serial visits document change more reliably than a single retrospective judgment.

An illustrative clinical formulation

Consider a person with a well-documented prior moderate cannabis use disorder. During the past fourteen months, the individual reports occasional cannabis use but no loss of control, harmful consequences, role impairment, or other DSM criteria apart from intermittent craving. After a careful assessment verifies the duration and absence of other criteria, a clinician using DSM-5-TR may determine that the cannabis use disorder is in sustained remission. Clinical counseling would still address impairment risks, the person's goals, and the possibility of future recurrence. An ICD-11 dependence classification would require its own distinct criteria and remission specification. This hypothetical example explains the diagnostic logic rather than offering an individual diagnosis.

Can remission last for years? What population research shows

Long-lasting remission is well documented, but published percentages vary because samples, substances, diagnostic criteria, and follow-up periods differ. Population surveys include people who never entered formal treatment, while specialized clinics often treat patients with more severe illness and greater comorbidity. Studies using DSM-IV dependence, DSM-5 SUD, self-identified recovery, and abstinence as outcomes are answering related but distinct questions. A percentage observed in one design should not be presented as the universal likelihood of recovery for every diagnosed patient.

A nationally representative analysis of 2012–2013 U.S. NESARC-III data examined adults who had experienced at least one DSM-5 SUD before the preceding year. Among this group, 14.2% reported past-year abstinence, 36.9% reported use without past-year disorder symptoms, 10.9% reported symptoms below the full disorder threshold, and 38.1% met a persistent or recurrent SUD diagnosis. Those categories describe a cross-sectional distribution among people with an earlier diagnosis; they are not the probabilities that a newly diagnosed patient will enter any particular category over the next year. They also do not establish that reduced symptoms necessarily imply low medical risk. McCabe et al., 2018.

In a three-year longitudinal analysis of 444 U.S. adults with DSM-IV cannabis abuse or dependence, approximately 67% no longer met the studied disorder threshold at follow-up, and a substantial fraction of those in remission had used cannabis. Those results demonstrate the possibility of both abstinent and nonabstinent remission, but the older classification, relatively small disorder-specific sample, and observational design limit transfer to present-day patients with high-potency products, complex comorbidities, or different exposure patterns. Natural outcome of cannabis use disorder.

Other follow-up studies establish that recurrence remains possible after remission. An older NESARC analysis of people with DSM-IV cannabis disorders in remission reported about 6.6% recurrence over an average follow-up of 3.6 years, with risk associated with shorter remission duration and certain psychiatric histories. This figure must be interpreted as an estimate from that particular previously remitted cohort, not as the relapse rate for people currently receiving treatment or the probability of any return to cannabis use. Flórez-Salamanca et al. study.

Why studies of alcohol, opioids, and cannabis cannot be pooled casually

Alcohol use disorder has a broad spectrum of severity and routes to improvement. Population epidemiology documents frequent reduction or resolution of alcohol problems across adulthood, while prolonged heavy use may leave medical consequences requiring care even after behavioral symptoms remit. Opioid use disorder is complicated by rapidly fatal overdose risk, drug supply changes, and the protective role of ongoing medications. Cannabis use disorder research includes cohorts exposed to different products and diagnostic definitions. Nicotine dependence has its own treatment patterns and physical health consequences. The disease course, the meaning of return to use, and the main hazards vary considerably by substance. NIAAA alcohol overview; CDC opioid guidance.

Prognosis: what makes sustained remission more or less likely?

Prognosis is a reasoned estimate of how a disorder may evolve. Its most relevant inputs include earlier severity and duration, past remission episodes, comorbidity, changes in stress and exposure, social and economic stability, and access to effective treatment. Longer symptom-free periods are informative, but duration alone does not provide certainty. The same past diagnosis can be followed by a wide range of trajectories, and prognosis should be revised when circumstances or treatment change.

Prior course and clinical severity

A history of repeated crises, marked impairment, multiple substances, or recurrent episodes may signal a need for closer monitoring and stronger continuity of care. Yet people with severe disorders also achieve sustained improvement, especially when treatment is sustained and practical barriers are addressed. Prognosis should not be reduced to the original symptom count. Prior responses to medications, counseling, and environmental changes contain clinically useful information; so do a person's preferences and capacities.

Stress, psychiatric comorbidity, and life circumstances

Longitudinal and survey analyses associate stressful life events and some psychiatric histories with persistence or recurrence. The NESARC-III analysis identified stressful life events as a common correlate across several disorder classes, although patterns differed by substance. Correlations can reflect many interacting pathways: stress may increase use or obstruct care, but substance-related difficulties can also contribute to stress and material insecurity. Age, employment, income, and treatment history likewise cannot be read as fixed causal explanations from observational comparisons. McCabe et al., 2018.

Co-occurring depression, anxiety, trauma-related symptoms, psychosis, pain, and sleep disturbances may affect daily coping, clinical safety, and adherence to treatment. These conditions require their own assessment and coordinated care rather than being automatically attributed to substance use. For a specific review of overlapping anxiety presentations, see Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity. Psychiatric symptom overlap must be understood in the context of both histories and the timing of exposure.

Social stability and recovery resources

Stable housing, accessible health care, trusted relationships, meaningful activity, and supportive communities can make continued improvement more practicable. Their protective roles are not interchangeable and differ according to local conditions, stigma, safety, and personal goals. The terms recovery capital and recovery support describe practical and social assets, but they must be measured carefully before assigning causal effects to individual programs. SAMHSA's health, home, purpose, and community framework is a useful guide to what standard diagnostic labels may overlook. SAMHSA recovery.

Neurobiology of remission and persistent vulnerability

Repeated substance exposure can influence incentive learning, cue associations, reinforcement, stress responses, and cognitive control. These mechanisms help explain why urges sometimes continue after major behavioral improvement. However, substance use disorders are heterogeneous clinical conditions; no single brain marker or dopamine-based model can determine whether an individual will remain in remission. Neurobiological findings must be integrated with exposure, developmental history, social context, and clinical observation.

Recovery may include changes in cognition and neurological functioning. A 2024 systematic review of longitudinal studies in adults with alcohol use disorder examined neuropsychological improvement following abstinence, finding that several cognitive functions can improve over time, while available studies differed in assessment methods and populations. Cognitive improvement and psychiatric remission are related but distinct outcomes: improvement in memory or executive functioning is not itself a DSM remission criterion, and substantial recovery may occur at different speeds. Powell et al., 2024.

How treatment supports remission and safer long-term outcomes

Effective treatment addresses the substance-specific disorder, medical and psychiatric needs, and the person's goals. It may include medication, evidence-based behavioral therapies, integrated care, social supports, and harm reduction. In many conditions, continued care is preferable to a single isolated episode. Successful withdrawal management can be an important acute service when clinically indicated, but it does not replace treatment for the underlying disorder. NIDA treatment and recovery; SAMHSA clinical recovery guidance.

Alcohol use disorder: treatment and the meaning of improvement

Medications such as naltrexone and acamprosate have evidence-based roles in alcohol use disorder treatment, supported by counseling and ongoing clinical follow-up when indicated. Treatment goals may include abstinence, cessation of heavy drinking, and improvement in health and functioning. The NIAAA research definition of AUD recovery deliberately includes reduction below heavy-drinking thresholds together with remission of disorder symptoms; individual medical circumstances can make abstinence the safest goal. Liver disease, pregnancy, relevant medications, a history of severe withdrawal, and previous loss of control can fundamentally change the risk assessment. NIAAA treatment and recovery; NIAAA research definitions.

Alcohol withdrawal may lead to seizures or delirium and can become life-threatening. A person with sustained heavy alcohol use or a history of complicated withdrawal should receive professional assessment before abrupt cessation. The decision about medically supervised withdrawal management depends on clinical risk; it cannot be replaced with generalized home detoxification instructions. ASAM alcohol withdrawal guideline.

Opioid use disorder: medication treatment is compatible with remission

Buprenorphine, methadone, and naltrexone are FDA-approved treatment medications for opioid use disorder. Selection requires an individualized clinical assessment, and these medications do not have identical effects or starting requirements. Methadone and buprenorphine treatment are associated with substantially lower overdose and overall mortality during treatment. The evidence strongly supports retention in appropriate care; leaving treatment is not a prerequisite for clinical recovery or diagnostic remission. CDC treatment guidance; Sordo et al. systematic review.

The 2017 systematic review and meta-analysis by Sordo and colleagues combined observational cohorts and found lower mortality rates while patients were receiving methadone or buprenorphine than during periods outside treatment. Because the comparisons were observational, selection and confounding remain possible, and the reported ratios should not be interpreted as the causal benefit expected for every patient. The overall direction is consistent with CDC guidance supporting effective medication treatment and warning against detoxification alone. Sordo et al., 2017; CDC guidance.

After a period of reduced or absent opioid exposure, tolerance can decline. Returning to previously tolerated amounts may cause respiratory depression and fatal overdose; fentanyl and combinations with alcohol or sedatives add risk. People at risk should have access to naloxone and emergency services, while evidence-based ongoing treatment remains central to prevention. During a suspected opioid overdose, especially when a person is unresponsive or breathing abnormally, emergency medical services are needed immediately; naloxone should be administered when available in accordance with emergency guidance. CDC opioid treatment guidance.

Cannabis, stimulants, and nicotine: different evidence bases

For cannabis use disorder, behavioral interventions such as motivational and cognitive behavioral approaches are widely used, while research continues on how to improve durable outcomes. The presence or absence of occasional cannabis use does not substitute for assessment of the person's current impairment and the risk of intoxication-related harms. For stimulant use disorder, the ASAM and American Academy of Addiction Psychiatry guideline identifies contingency management as a central evidence-based treatment approach, while medication evidence remains more limited and substance-specific. ASAM and AAAP stimulant guideline.

For tobacco use disorder, evidence-based cessation medications and behavioral support can improve quit outcomes. Continued smoking-related exposure carries health risks even when some behavioral difficulties lessen. Any prognosis discussion must specify the substance rather than treating a nonabstinent outcome as equally acceptable for all psychoactive exposures. The absence of active diagnostic criteria and the magnitude of remaining health risk are separate clinical questions.

Benzodiazepines: dependence, withdrawal, and medical supervision

Physiological dependence on prescribed benzodiazepines can develop without benzodiazepine use disorder. When dependence is present, abrupt discontinuation may provoke severe withdrawal, including seizures. A 2025 multisociety ASAM-led guideline recommends clinical assessment and individualized supervised tapering when discontinuation is appropriate. Patients should not use a perceived period of remission as a reason to stop prescribed medication suddenly. The guideline itself recognizes limitations in the evidence for specific tapering schedules and draws substantially on clinical consensus. ASAM Joint Clinical Practice Guideline on Benzodiazepine Tapering.

What happens if substance use resumes after remission?

A return to use must be evaluated by its context, amount, resulting harm, and relationship to the diagnostic criteria. One episode of alcohol use, for example, does not automatically prove a recurrence of alcohol use disorder. A return to multiple symptoms of impaired control and continued use despite harm, however, may require reassessment for an active disorder. With opioids, clinical danger may be immediate even before a new diagnosis can be established. Person-centered documentation states what happened and which responses are needed.

A clinical response commonly involves reassessing overdose and withdrawal risks, the circumstances preceding the event, other symptoms, medication access, and the patient's safety. Care may need adjustment, more frequent contact, renewed treatment engagement, or practical help with housing, relationships, and mental health. Shaming, removing all support, or assuming an individual has lost the value of previous progress can worsen disengagement. NIAAA describes return to drinking as a signal to examine and adjust care rather than a definitive verdict on treatment success. NIAAA Understanding Relapse.

A return to use and recurrence of the disorder are distinct outcomes

Research frequently reports a relapse rate without specifying whether relapse means any substance exposure, heavy drinking, exceeding a laboratory threshold, return of multiple DSM criteria, hospitalization, or re-entry to care. Such studies cannot be compared without examining the outcome definition. An effective study identifies its event, timeframe, population, and missing-data method. A clinical note should likewise differentiate observed use, safety consequences, and diagnostic recurrence.

Monitoring remission in long-term clinical care

Monitoring starts with the person's goals and the underlying risks. Follow-up may review SUD symptoms, cravings, exposure, sleep, mood, medical complications, prescribed treatment, social functioning, and treatment satisfaction. Measures of alcohol consumption or other substance use may be useful, but they should be interpreted alongside functioning, physical health, and diagnostic status. Depending on the situation, toxicology or other biomarkers may contribute to care; they are not substitutes for a respectful, comprehensive assessment.

Clinicians can document the date the last relevant diagnostic criterion was present, the interval meeting remission conditions, whether craving persists, the setting in which improvement occurred, medications used, and what protective supports are in place. Such specificity improves continuity when people change providers and helps researchers distinguish clinical course from consumption patterns. Documentation can also identify emerging problems while remaining realistic about uncertainty and the individual's agency.

Population-specific considerations

Adolescents and young adults

Substance exposure, executive development, peer environments, family circumstances, and education interact during adolescence and early adulthood. Remission assessment still requires substance-specific diagnostic reasoning, but clinicians must address developmental context, confidentiality, safety, and family or trusted-adult involvement as appropriate. A cohort's favorable average outcome does not justify postponing intervention for an individual experiencing serious impairment.

Pregnancy and postpartum care

Pregnancy changes the safety implications of alcohol, opioids, sedatives, and other drugs. People with opioid use disorder need prompt evidence-based obstetric and addiction care; medication treatment may be essential to maternal and fetal safety. The postpartum period introduces additional stressors and overdose risks. Abrupt medically unsupervised withdrawal or medication changes may be hazardous. Remission assessment and prenatal safety planning require distinct, coordinated clinical decisions. CDC opioid treatment guidance.

Older adults and people with complex medical needs

Older adults may have different medication interactions, altered metabolism, falls risk, chronic pain, and cognitive difficulties. Multiple substances, including alcohol mixed with sedating prescriptions, can create acute dangers despite fewer visible behavioral symptoms. Clinicians may need a medication reconciliation, a more extensive differential diagnosis, and tailored monitoring of function and safety. A diagnostic remission label does not erase cardiovascular, hepatic, neurological, or other health consequences of prior exposure.

Co-occurring mental disorders and trauma

Depression, anxiety, trauma-related symptoms, psychosis, and other conditions may change both the course of substance use and the experience of recovery. A substance-induced syndrome requires attention to the temporal relationship with intoxication or withdrawal; an independent disorder may need continuing treatment after substance use symptoms remit. Relevant adjacent analyses include Substance-Induced Psychosis: Causes, Symptoms, and Treatment and Schizophrenia and Substance Use Disorders: Dual-Diagnosis Care. Clinical evaluation must avoid attributing all psychiatric symptoms to a single cause.

Evidence quality and the limits of prognosis

The strongest evidence for a diagnostic definition comes from authoritative classification materials. Evidence for the distribution of outcomes comes from longitudinal cohorts and representative surveys. Treatment efficacy should be judged using randomized trials, systematic reviews, and clinical guidelines suited to each substance. These evidence classes answer different questions. A validated diagnostic rule tells clinicians how to classify present symptoms; it does not predict a person's future with the certainty of a biological test.

The broad existence of remission is established. The exact probability, expected timeframe, and best intervention for a particular individual are more uncertain. Surveys may miss people experiencing homelessness, incarceration, severe illness, or death; retrospective reports can undercount symptoms; studies may exclude polysubstance exposure and complex co-occurring disorders. Comparison groups in treatment cohorts can differ in illness severity, access, and motivation. Longer follow-up can reveal both sustained functioning and late recurrence that shorter studies cannot identify.

Remission after treatment cannot always be attributed entirely to that treatment because people also change with age, relationships, living conditions, and other events. Equally, spontaneous or natural recovery observed in surveys does not prove that care is unnecessary for a person with an active severe condition. Treatment evidence, current risks, and patient-specific circumstances remain indispensable to sound clinical decision-making. McCabe et al., 2018; NIAAA AUD research overview.

Frequently asked clinical questions

Is early remission the same as recovery?

Early remission is a DSM-5-TR specifier reached after at least three months and less than twelve months without diagnostic criteria other than craving. Recovery also addresses health, material stability, relationships, functioning, and personal aims. Someone can qualify for early remission while still building these aspects of recovery.

Does twelve months of remission mean the disorder is gone forever?

Twelve months qualifies as sustained remission under DSM-5-TR when all applicable conditions are met. It records a meaningful period of clinical improvement. Continued functioning, risk, and the need for ongoing treatment must be evaluated separately, since later recurrence remains possible.

Can a person be in remission while taking methadone or buprenorphine?

Yes. Evidence-based medications for opioid use disorder may be part of ongoing care during remission. Appropriate treatment does not invalidate the condition of sustained improvement. Stopping medication to meet an informal abstinence ideal can increase risk and should never be presumed clinically beneficial. CDC guidance.

Can substance use disorder remit without residential rehabilitation?

Yes. Remission may develop with outpatient care, medication, community support, mutual help, personal changes, or combinations of these. Some people improve without formal treatment, but severe withdrawal risk, repeated overdose, significant psychiatric symptoms, and other medical conditions require professional intervention. The appropriate setting depends on clinical needs rather than a universal recovery pathway.

Does one drink, one craving, or one return to use restart the remission clock?

Craving alone does not restart the DSM remission clock. An episode of use must be assessed for whether another diagnostic criterion has reappeared; by itself, use is not equivalent to a renewed SUD diagnosis. However, immediate medical risk can arise without diagnostic recurrence, and some personal or research abstinence definitions are stricter than DSM remission. The specific classification and individualized care plan govern documentation.

Does a negative drug screen prove sustained remission?

No. A test describes selected substances within a limited detection window and is affected by assay characteristics. Sustained remission requires clinical knowledge of prior diagnosis and symptoms across at least twelve months. Testing may support clinical care but cannot establish the entire course on its own.

What if someone feels hopeless, confused, or physically unsafe during recovery?

Immediate safety takes priority over formal remission classification. An unresponsive person, dangerously slow or absent breathing, a seizure, severe confusion, chest pain, or a person at imminent risk of self-harm requires emergency medical assessment. Possible alcohol or benzodiazepine withdrawal should be assessed urgently, particularly with a history of severe withdrawal. Medical emergencies should be handled through local emergency services rather than self-directed detoxification or postponed appointments.

Clinical synthesis

Substance use disorder can enter early or sustained remission, and many people sustain meaningful improvement. DSM-5-TR uses a symptom-based remission rule with a craving exception: at least three months for early remission and at least twelve months for sustained remission. ICD-11 substance dependence uses different course definitions, often distinguishing full abstinent remission from partial remission after marked reduction. Clinical assessment must name the system, prior disorder, substance, interval, ongoing symptoms, and treatment circumstances.

Prognosis is best understood as a dynamic clinical judgment. Long-term outcomes are shaped by substance-specific risks, previous course, treatment access, physical and mental health, and the environments in which people live. Remission is an important milestone, while recovery includes the ongoing development of health and functioning. For people receiving opioid medications, staying in effective treatment can be lifesaving; for alcohol or benzodiazepine dependence, safe withdrawal planning requires medical judgment. A sustained remission designation can coexist with continued care, active self-direction, and meaningful long-term recovery.

Related Articles

Cluster Substance Use Disorders and Addiction Recovery — The central scientific chapter on diagnosis, mechanisms, treatment, harm reduction, and recovery across substance classes.

Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity — The relationship between anxiety symptoms, substance exposure, and co-occurring disorders.

Neuroticism and Addiction: Substance Use, Negative Affect, and Risk — Personality-related risk, negative affect, and substance-use patterns.

Schizophrenia and Substance Use Disorders: Dual-Diagnosis Care — Coordinating treatment when severe mental illness and substance use disorder coexist.

Substance-Induced Psychosis: Causes, Symptoms, and Treatment — Distinguishing acute and persistent psychiatric symptoms related to exposure.

Growing Up With Parental Substance Use: Childhood Adversity and Adult Outcomes — Family and developmental consequences of parental substance-related problems.

What Is Addiction Recovery? Remission, Functioning, and Support — definitions of recovery, functioning, remission, and multiple recovery pathways.

How Long Does Addiction Recovery Take? Timelines and Outcome Research — variable trajectories, retention, remission, recurrence, and long-term outcomes.

Relapse in Addiction Recovery: Warning Signs, Risk, and Response — recurrence of substance use, predictors, response, and ongoing care planning.

References

American Society of Addiction Medicine. (2020). The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. Official guideline.

American Society of Addiction Medicine and American Academy of Addiction Psychiatry. (2024). Clinical Practice Guideline on the Management of Stimulant Use Disorder. Peer-reviewed clinical guideline.

American Society of Addiction Medicine and partner organizations. (2025). Joint Clinical Practice Guideline on Benzodiazepine Tapering. Official guideline.

Centers for Disease Control and Prevention. (2024). Opioid Use Disorder: Treating. Official clinical guidance.

Flórez-Salamanca, L., et al. (2013). Probability and predictors of cannabis use disorders relapse: Results of the National Epidemiologic Survey on Alcohol and Related Conditions. PubMed Central.

Hagman, B. T., Falk, D., Litten, R., and Koob, G. F. (2022). Defining Recovery From Alcohol Use Disorder: Development of an NIAAA Research Definition. American Journal of Psychiatry, 179(11), 807–813. https://doi.org/10.1176/appi.ajp.21090963.

Hasin, D. S., et al. (2013). DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationale. American Journal of Psychiatry, 170(8), 834–851. https://doi.org/10.1176/appi.ajp.2013.12060782.

McCabe, S. E., West, B. T., Strobbe, S., and Boyd, C. J. (2018). Persistence/Recurrence and Remission from DSM-5 Substance Use Disorders in the United States: Substance-Specific and Substance-Aggregated Correlates. Journal of Substance Abuse Treatment, 93, 38–48. https://doi.org/10.1016/j.jsat.2018.07.012.

National Institute on Alcohol Abuse and Alcoholism. (n.d.). Alcohol Use Disorder: From Risk to Diagnosis to Recovery. Clinical resource.

National Institute on Alcohol Abuse and Alcoholism. (n.d.). NIAAA Recovery Research Definitions. Official research definitions.

National Institute on Drug Abuse. (n.d.). Treatment and Recovery. Official scientific resource.

National Institutes of Health. (n.d.). Alcohol and Substance Use: Inclusive Language. Editorial guidance.

Powell, A., Sumnall, H., Smith, J., Kuiper, R., and Montgomery, C. (2024). Recovery of neuropsychological function following abstinence from alcohol in adults diagnosed with an alcohol use disorder: Systematic review of longitudinal studies. PLOS ONE, 19(1), e0296043. https://doi.org/10.1371/journal.pone.0296043.

Sordo, L., et al. (2017). Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ, 357, j1550. https://doi.org/10.1136/bmj.j1550.

Substance Abuse and Mental Health Services Administration. (2023). Counseling Approaches to Promote Recovery From Problematic Substance Use and Related Issues. Treatment Improvement Protocol 65. NCBI Bookshelf.

Substance Abuse and Mental Health Services Administration. (2024). About Recovery. Official recovery guidance.

World Health Organization. (2024). Clinical Descriptions and Diagnostic Requirements for ICD-11 Mental, Behavioural or Neurodevelopmental Disorders. WHO publication.